Avacta Group Plc (AVCTF)
USD 0.52
(0.0%)
USD 0.52
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -23.04 Million GBP | 10.91% |
| 2022 | -25.86 Million GBP | 3.08% |
| 2021 | -26.69 Million GBP | -53.79% |
| 2020 | -17.35 Million GBP | -91.11% |
| 2019 | -9.08 Million GBP | -19.88% |
| 2018 | -7.57 Million GBP | -18.4% |
| 2017 | -6.39 Million GBP | -44.82% |
| 2016 | -4.41 Million GBP | -70.98% |
| 2015 | -2.58 Million GBP | -67.79% |
| 2014 | -1.54 Million GBP | -2.26% |
| 2013 | -1.5 Million GBP | -10.33% |
| 2012 | -1.36 Million GBP | -49.18% |
| 2011 | -915 Thousand GBP | 36.9% |
| 2010 | -1.45 Million GBP | 20.81% |
| 2009 | -1.83 Million GBP | -21.07% |
| 2008 | -1.51 Million GBP | -35.76% |
| 2007 | -1.11 Million GBP | -743.94% |
| 2006 | -132 Thousand GBP | 27.87% |
| 2005 | -183 Thousand GBP | 28.24% |
| 2004 | -255 Thousand GBP | -240.0% |
| 2003 | -75 Thousand GBP | 36.97% |
| 2002 | -119 Thousand GBP | -21.43% |
| 2001 | -98 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -5.09 Million GBP | 65.67% |
| 2023 Q2 | -9.46 Million GBP | -85.62% |
| 2023 FY | - GBP | 10.91% |
| 2023 Q4 | -13.58 Million GBP | -111.41% |
| 2023 Q3 | -6.42 Million GBP | 32.07% |
| 2022 Q2 | -7.67 Million GBP | -82.07% |
| 2022 Q3 | -7.95 Million GBP | -3.64% |
| 2022 FY | - GBP | 3.08% |
| 2022 Q1 | -4.21 Million GBP | 74.37% |
| 2022 Q4 | -14.84 Million GBP | -86.6% |
| 2021 Q3 | -8.54 Million GBP | 16.69% |
| 2021 Q2 | -10.25 Million GBP | -89.24% |
| 2021 Q4 | -16.45 Million GBP | -92.51% |
| 2021 Q1 | -5.42 Million GBP | 47.2% |
| 2021 FY | - GBP | -53.79% |
| 2020 Q4 | -10.26 Million GBP | -88.87% |
| 2020 Q1 | -3.78 Million GBP | 0.0% |
| 2020 Q2 | -6.91 Million GBP | -82.48% |
| 2020 FY | - GBP | -91.11% |
| 2020 Q3 | -5.43 Million GBP | 21.4% |
| 2019 Q2 | -2.13 Million GBP | 0.0% |
| 2019 FY | - GBP | -19.88% |
| 2019 Q1 | -2.13 Million GBP | 55.72% |
| 2018 Q1 | -2.53 Million GBP | -43.04% |
| 2018 FY | - GBP | -18.4% |
| 2018 Q4 | -4.81 Million GBP | 0.0% |
| 2018 Q2 | -3.86 Million GBP | -52.19% |
| 2017 Q2 | -1.95 Million GBP | 0.0% |
| 2017 Q4 | -1.77 Million GBP | 0.0% |
| 2017 FY | - GBP | -44.82% |
| 2017 Q1 | -1.95 Million GBP | -24.24% |
| 2017 Q3 | -1.77 Million GBP | 9.0% |
| 2016 Q2 | -1.65 Million GBP | 0.0% |
| 2016 FY | - GBP | -70.98% |
| 2016 Q3 | -1.57 Million GBP | 5.14% |
| 2016 Q4 | -1.57 Million GBP | 0.0% |
| 2016 Q1 | -1.65 Million GBP | -89.68% |
| 2015 Q4 | -872.5 Thousand GBP | 0.0% |
| 2015 FY | - GBP | -67.79% |
| 2015 Q3 | -872.5 Thousand GBP | -34.65% |
| 2015 Q2 | -648 Thousand GBP | 0.0% |
| 2015 Q1 | -648 Thousand GBP | 3.64% |
| 2014 Q2 | -550 Thousand GBP | 0.0% |
| 2014 Q1 | -550 Thousand GBP | -208.99% |
| 2014 Q4 | -672.5 Thousand GBP | 0.0% |
| 2014 FY | - GBP | -2.26% |
| 2014 Q3 | -672.5 Thousand GBP | -22.27% |
| 2013 FY | - GBP | -10.33% |
| 2013 Q2 | -371 Thousand GBP | 0.0% |
| 2013 Q3 | -178 Thousand GBP | 52.02% |
| 2013 Q4 | -178 Thousand GBP | 0.0% |
| 2013 Q1 | -371 Thousand GBP | 12.81% |
| 2012 Q4 | -425.5 Thousand GBP | 0.0% |
| 2012 FY | - GBP | -49.18% |
| 2012 Q3 | -425.5 Thousand GBP | 0.0% |
| 2011 FY | - GBP | 36.9% |
| 2010 FY | - GBP | 20.81% |
| 2009 FY | - GBP | -21.07% |
| 2008 FY | - GBP | -35.76% |
| 2007 FY | - GBP | -743.94% |
| 2006 FY | - GBP | 27.87% |
| 2005 FY | - GBP | 28.24% |
| 2004 FY | - GBP | -240.0% |
| 2003 FY | - GBP | 36.97% |
| 2002 FY | - GBP | -21.43% |
| 2001 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 67.557% |
| SQZ Biotechnologies Company | -64.14 Million USD | 64.07% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -771.486% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -32.677% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 124.507% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1400.343% |
| Mesoblast Limited | -62.38 Million USD | 63.061% |
| Marizyme, Inc. | -34.28 Million USD | 32.774% |
| Genus plc | 73.7 Million USD | 131.27% |
| Pharming Group N.V. | 9.87 Million USD | 333.33% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1449.403% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -549.733% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -162.722% |
| ContraFect Corporation | -64.99 Million USD | 64.544% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1544.02% |
| IMV Inc. | -35.52 Million USD | 35.124% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -891.729% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -4348.64% |
| ONE Bio Corp. | 13.61 Million USD | 269.294% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 52.213% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 745.185% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3544.178% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -908.803% |
| Biomind Labs Inc. | -1.03 Million USD | -2127.637% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -696.798% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -221.814% |
| Skye Bioscience, Inc. | -13.54 Million USD | -70.112% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 342842.415% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -92084.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -493.308% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -45.22% |
| GB Sciences, Inc. | -1.41 Million USD | -1523.089% |
| Alpha Cognition Inc. | -9.7 Million USD | -137.451% |
| CSL Limited | 4.78 Billion USD | 100.481% |
| Agentix Corp. | -1.37 Million USD | -1580.036% |
| Enzolytics Inc. | -2.12 Million USD | -986.036% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -652.396% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 89.332% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 58.355% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1993.673% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 360.295% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 6183.243% |
| Zenith Capital Corp. | -8.6 Million USD | -167.79% |
| Genscript Biotech Corporation | -248.71 Million USD | 90.734% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -288.706% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -9536.63% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -842.014% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -12992.506% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -1099.743% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -248.574% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -409.169% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -515.147% |
| Helix BioMedix, Inc. | -1.04 Million USD | -2102.593% |
| EV Biologics, Inc. | -1.26 Million USD | -1718.753% |
| Q BioMed Inc. | -617.62 Thousand USD | -3631.372% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1216.915% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 41.857% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -205.098% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -821.117% |
| HST Global, Inc. | -5303.00 USD | -434484.198% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1020.369% |
| Halberd Corporation | -74.27 Thousand USD | -30926.266% |
| Resverlogix Corp. | -11.74 Million USD | -96.27% |
| Cell Source, Inc. | -4.27 Million USD | -439.4% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -6175.785% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -2359.686% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1437.521% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -277.022% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -132188.617% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -2127.103% |
| Kadimastem Ltd | -2.62 Million USD | -778.15% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -5970.808% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -12626.409% |
| LadRx Corporation | 412.28 Thousand USD | 5689.85% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1672.08% |
| Affymax, Inc. | -14.29 Million USD | -61.217% |
| Itoco Inc. | -1.86 Million USD | -1133.069% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1965.054% |
| Mobile Lads Corp. | -2.24 Million USD | -928.307% |
| CytoDyn Inc. | -18.02 Million USD | -27.827% |
| International Stem Cell Corporation | 202 Thousand USD | 11508.911% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -503.275% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -29061.447% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -188353.676% |
| Qrons Inc. | -40.08 Thousand USD | -57398.565% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -4645.119% |
| SYBLEU INC | -141.57 Thousand USD | -16178.758% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 4469.465% |
| Rebus Holdings, Inc. | -951 Thousand USD | -2323.344% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -2070.036% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -43680.395% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -836.094% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 35.75% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -51113.333% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -741.709% |
| Neutra Corp. | -181.24 Thousand USD | -12615.245% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -14.321% |
| PureTech Health plc | -11.62 Million USD | -98.211% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -14.329% |
| IXICO plc | -707 Thousand USD | -3159.689% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -199.883% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 52.331% |
| CSL Limited | 4.73 Billion USD | 100.487% |
| Cellectis S.A. | -92.63 Million USD | 75.122% |